Home > Healthcare > Joint Pain Injections Market

Joint Pain Injections Market - by Injection type (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet Rich Plasma Injections), By Joint type (Knee, Shoulder & Elbow, Ankle & Hip), By End-use (Hospitals, Clinics) & Global Forecast, 2023-2032

  • Report ID: GMI5403
  • Published Date: Mar 2023
  • Report Format: PDF

Joint Pain Injections Market Size

Joint Pain Injections Market size surpassed USD 3.74 billion in 2022 and is estimated to witness 8.7% CAGR between 2023 and 2032. This significant market growth is majorly pertaining to several factors including the Rising prevalence of arthritis and key players in the market are focusing on developing innovative products to meet customers demand and increase their market share.

Joint Pain Injections Market

To understand key trends  
Download Free Sample

Joint discomfort is particularly common in elderly population as result of pre-existing illness and diseases. Musculoskeletal conditions such as arthritis sacroiliac joint pain inflammation could contribute to joint discomfort. Injections for joint pain are usually administrated directly into the joint to relive and minimize the swelling and discomfort. The growing elderly population and the high prevalence of obesity drive up demand for joint pain treatment options. To meet this rising demand, platelet-rich plasma (PRP) is created from the patient's own blood and then injected into a painful joint to relieve pain and stiffness associated with arthritis. Thus, the development of such advanced techniques provides opportunities for investment by key market players, which will further drive market expansion.

High cost of joint pain injections is restraining the market growth. Therefore, the prevalence of musculoskeletal disorders will catalyze the growth of the market. The increase in demand for effective treatment increases the demand for products. However, the market growth is hindered by the high price of joint injections. Additionally, strict product approval regulations are hindering the overall market demand.

Therapeutics advantages to relieve joint pain & inflammation will drive the market growth

The growth of the joint pain injections market is expected to be influenced by the increase in the incidence of joint pain in developed and developing countries and the rapid development of injections that enable doctors to analyze the root causes of pain and help to relieve pain quickly. Facet joint injections contain a small amount of numbing medicine that numbs the muscles, ligaments, and joint capsules. Increased demand for non-surgical treatment has been identified as a critical factor affecting the effectiveness of joint injections during the forecast period. It is also expected to contribute to the total accumulation of facet joint injections during the evaluation period, thus improving the focus on effective pain relief.

Joint Pain Injections Market Analysis

Global joint pain injections market Size ,By Injection Type ,2022& 2032 (USDMillion))

To understand key market trends  
Download Free Sample

Based on injection type, the joint pain injections market is segmented as hyaluronic acid injection, corticosteroid injection and platelet rich plasma injection. the hyaluronic acid injection segment held a dominant market share in 2022. Furthermore, human joints are constantly subjected to wear and tear, hyaluronic acid, like synovial fluid, has excellent lubricating and shock-absorbing properties that help to reduce joint stiffness and discomfort. The anti-inflammatory properties of hyaluronic acid and ability to provide short-term relief in joint sprains suffered by athletes and industrial workers, corticosteroid injections are used as an adjuvant drug in joint pain. Thus, rising demand for hyaluronic acid injections would drive the overall market statistics.

Based on joint type, the joint pain injections market is segmented as knee, shoulder & elbow, and ankle & hip. The knee segment held a dominated the market in 2022, whereas the hip joint segment is expected to grow with a highest CAGR, owing to the rise in the number of accidents and injuries related to the accidents leading to the hip joint pain and rise in the number of geriatric patients.

Global joint pain injections market Share, By End Use,2022 (%)

To understand key market trends  
Download Free Sample

Based on end-use the Joint Pain Injections market is segmented as hospitals, clinics, and others. The hospitals segment is estimated to show a lucrative CAGR of over 8.9% through 2032. This high segmental share is attributed to availability of wide varieties of injections in the hospitals or in hospitals pharmacies. Strong end-uses and extensive network of suppliers to hospitals assists to reach a wide customer base and manage consumer compliance. Segment expansion is due to huge need for hospitalization by people with orthopedic diseases.

Global joint pain injections market by region

To understand regional trends  Download Free Sample

U.S. Joint Pain Injections Market is anticipated to reach more than USD 4 billion by 2032. The significant market share is owing to several factors including presence of major market players, and the high prevalence of musculoskeletal problems that cause joint aches. Public awareness of non-invasive orthopaedic therapies has grown, as has implant technology innovation and sophisticated healthcare facilities.

According to the Centres for Disease Control and Prevention, chronic pain caused by arthritis affects millions of people in the United States each year. Arthritis affects one out of every four people, and 15 million people report significant joint pain because of it. One of the factors driving the regional market statistics. Furthermore, major market competitors are heavily investing in research, which will benefit the North American industry.

Joint Pain Injections Market Share

Some of the major market players operating in the joint pain injection industry is :

  • The Zimmer Biomet
  • Anika Therapeutics, Inc.
  • Bioventus
  • Sanofi
  • Pacira Biosciences (Flexion)
  • OrthogenRx
  • Pfizer
  • Ferring B.V.
  • Lifecore Biomedical
  • Wright Medical Group (Stryker)
  •  Emcyte Corporation
  • Stryker 

Market players are focusing on the introduction of Visco supplements.

Moreover, increasing awareness of joint pain injections is catalyzing market growth across the region. Rapid adoption of technologically advanced pain management solutions will significantly contribute to the market demand. increasing R&D initiatives by the key market players and advances such as single injection therapy and plasma matrix therapy, will provide lucrative opportunities for the market players to invest and lead to the market growth.

Recent industry developments:

  • In March 2023, Green Roads, a subsidiary of the Valens Company, made a USD 120,000 donation to the Arthritis Foundation in support of the organization's pain management initiative to advance the improved quality of life for those who live with chronic pain. This donation made Green Roads an official supporting sponsor of the Arthritis Foundation.
  • In January 2023, AbbVie received the United States Food and Drug Administration (FDA) approval for SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), which can be administered with a single injection four times a year.

Impact of COVID-19 pandemic

The COVID-19 pandemic arose as a global health pandemic, imposing significant medical burden and financial adversity on various sectors of the global economy. Several industries, including healthcare, have predicted significant transitions in the first half of 2020. The joint pain injections industry also witnessed a setback during the initial phase of the pandemic due to disruption of the supply chain across the globe. Many key market players saw a decrease in revenue from the joint pain injection segments, owing to a decrease in patient visits to hospitals, reallocation of healthcare rejoint types, and the effect on the global supply chain. However, during the second phase of the pandemic the demand of joint pain injection has increased due to increasing awareness among people regarding the importance of health and technological advancement in the market.

Joint Pain Injections Market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By injection type

  • Hyaluronic acid injections
  • Corticosteroid injections
  • Platelet rich plasma injections

By joint type

  • Knee
  • Shoulder & elbow
  • Ankle & hip
  • Others

By end use

  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia  
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for joint pain injections stood at over USD 3.5 billion in 2022 and is anticipated to showcase more than 8.5% CAGR from 2023 to 2032 owing to a significant rise in the prevalence of musculoskeletal conditions and orthopedic disorders.

Joint pain injection industry size from the hospital segment is expected to amass over USD 5.4 billion by 2032 owing to the easy accessibility to advanced medical equipment and skilled orthopedic surgeons across these facilities.

North America joint pain injection market is projected to witness more than 7.5% CAGR between 2023 and 2032 driven by the consistent rise in the geriatric population and strong competitive landscape across the region.

Prominent enterprises operating in the global market include Zimmer Biomet, Anika Therapeutics, Inc., Bioventus, Sanofi, Pfizer, and others

Joint Pain Injections Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 197
  • Countries covered: 18
  • Pages: 180
 Download Free Sample